US 12,312,415 B2
Anti-KLK7 antibodies, anti-KLK5 antibodies, multispecific anti-KLK5/KLK7 antibodies, and methods of use
James Thomas Koerber, San Mateo, CA (US); Wyne Pun Lee, Millbrae, CA (US); Tangsheng Yi, Belmont, CA (US); Juan Zhang, Palo Alto, CA (US); Cary Dean Austin, San Carlos, CA (US); Cecilia P.C. Chiu, Redwood City, CA (US); Joseph Edward Chavarria-Smith, San Francisco, CA (US); and Jawahar Sudhamsu, San Francisco, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Dec. 19, 2023, as Appl. No. 18/389,748.
Application 18/389,748 is a division of application No. 17/024,094, filed on Sep. 17, 2020.
Claims priority of provisional application 62/901,990, filed on Sep. 18, 2019.
Prior Publication US 2024/0150491 A1, May 9, 2024
Int. Cl. C07K 16/40 (2006.01); A61K 39/395 (2006.01); A61P 17/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 39/3955 (2013.01); A61P 17/00 (2018.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 48 Claims
 
1. An antibody that binds to human KLK5, wherein the antibody comprises:
a) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 68, (b) CDR-H2 comprising the amino acid sequence of SEQ ID NO: 70, and (c) CDR-H3 comprising an amino acid sequence selected from SEQ ID NOs: 71 and 72, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 73, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 74, and (f) CDR-L3 comprising an amino acid sequence selected from SEQ ID NOs: 75-78; or
b) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 68, (b) CDR-H2 comprising an amino acid sequence selected from SEQ ID NOs: 69 and 70, and (c) CDR-H3 comprising the amino acid sequence of SEQ ID NO: 72, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 73, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 74, and (f) CDR-L3 comprising an amino acid sequence selected from SEQ ID NOs: 75-78; or
c) a heavy chain variable domain (VH) comprising (a) CDR-H1 comprising the amino acid sequence of SEQ ID NO: 68, (b) CDR-H2 comprising an amino acid sequence selected from SEQ ID NOs: 69 and 70, and (c) CDR-H3 comprising an amino acid sequence selected from SEQ ID NOs: 71 and 72, and a light chain variable domain (VL) comprising (d) CDR-L1 comprising the amino acid sequence of SEQ ID NO: 73, (e) CDR-L2 comprising the amino acid sequence of SEQ ID NO: 74, and (f) CDR-L3 comprising an amino acid sequence selected from SEQ ID NOs: 75-78.